CardioRenal, a Grenoble-based company that specializes at improving the treatment at home of patients with severe chronic renal disease (CKD), has raised 3.3M in seed financing.
French entrepreneurs and long-standing shareholders of companies (the management) were the backers.
The company intends use the funds to continue its plan to get regulatory and clinical approvals in order to prepare for the CE marking in 2023 of its integrated tool.
Led by Maurice Bérenger, CEO, CardioRenal specializes in improving treatment at home for patients with severe chronic kidney disease (CKD). The platform allows doctors to monitor key blood biomarkers remotely and optimize patient care.
CardioRenal conducted a clinical trial using the technology in October 2021. The results of this trial will be presented at the European Renal Association congress in Paris, France, in May.